Results 31 to 40 of about 11,842 (181)

Formyl peptide receptor as a novel therapeutic target for anxiety-related disorders. [PDF]

open access: yesPLoS ONE, 2014
Formyl peptide receptors (FPR) belong to a family of sensors of the immune system that detect microbe-associated molecules and inform various cellular and sensorial mechanisms to the presence of pathogens in the host.
Irene Gallo   +7 more
doaj   +1 more source

Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1

open access: yesScientific Reports, 2017
Formyl peptide receptor 1 (FPR1) mediates bacterial and mitochondrial N-formyl peptides-induced neutrophil activation. Therefore, FPR1 is an important therapeutic target for drugs to treat septic or sterile inflammatory diseases.
Fu-Chao Liu   +7 more
doaj   +1 more source

Bioinformatics analysis identifies potential biomarkers for the prediction and treatment of myocardial infarction

open access: yesCardiology Plus, 2021
Objectives: The aim of this study was to identify differentially expressed genes (DEGs) related to myocardial infarction (MI), which may serve as research and therapeutic targets.
Yu-Yao Ji   +5 more
doaj   +1 more source

Ac2-26 mitigated acute respiratory distress syndrome rats via formyl peptide receptor pathway

open access: yesAnnals of Medicine, 2021
Background Acute respiratory distress syndrome (ARDS) is characterized by severe local and systemic inflammation. Ac2-26, an Annexin A1 Peptide, can reduce the lung injury induced by reperfusion via the inhibition of inflammation.
Yingnan Ju   +4 more
doaj   +1 more source

Expression and Signaling of Formyl-Peptide Receptors in the Brain

open access: yesNeurochemical Research, 2010
The human formyl-peptide receptor (FPR) and its variants FPRL1 and FPRL2 belong to the G-protein coupled seven transmembrane receptor (GPCR) family sensitive to pertussis toxin. FPR and FPRL1 were first detected in phagocytic leukocytes, and FPRL2 was found in monocytes and in dendritic cells.
CATTANEO, FABIO   +2 more
openaire   +3 more sources

Differential activation of polymorphisms of the formyl peptide receptor by formyl peptides

open access: yesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2007
We have investigated the role of two polymorphic sites (R190W and N192K) on the binding and activation of the formyl peptide receptor (FPR) by viral and formyl peptides. WEDWVGWI, a peptide with antiviral activity derived from the membrane proximal region of feline immunodeficiency virus, binds with high affinity to FPR.
openaire   +3 more sources

Formyl Peptide Receptor 1 and 2 Dual Agonist Inhibits Human Neutrophil Chemotaxis by the Induction of Chemoattractant Receptor Cross-desensitization

open access: yesJournal of Pharmacological Sciences, 2011
Formyl peptide receptor 1 (FPR1) and FPR2/ALX are known to control neutrophil chemotaxis in response to various ligands. In this study, we investigated the inhibitory mechanism of compound 43 (Cpd43), an FPR1 and FPR2/ALX dual agonist, on human ...
Yoshitaka Sogawa   +3 more
doaj   +1 more source

A Ganoderma-Derived Compound Exerts Inhibitory Effect Through Formyl Peptide Receptor 2

open access: yesFrontiers in Pharmacology, 2020
Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) widely expressed in neutrophils and other phagocytes. FPRs play important roles in host defense, inflammation, and the pathogenesis of infectious and inflammatory diseases.
Huirong Wang   +10 more
doaj   +1 more source

An independent predictor of poor prognosis in locally advanced rectal cancer: rs867228 in formyl peptide receptor 1 (FPR1)

open access: yesOncoImmunology, 2021
Formyl peptide receptor 1 (FPR1) plays a key regulatory role in innate and adaptive immunity. Recently, we reported that the CC genotype of FPR1-E346A (rs867228, c. 1037 A > C) is an independent biomarker for patients with locally advanced rectal cancer (
Shu-Fen Chiang   +5 more
doaj   +1 more source

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

open access: yesAdvanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy